MAPK3 and acute myeloid leukemia: According to Jasek Gajda et al., another combination of pharmacological agents, namely ZSTK474 (PI3K inhibitor) and AZD0364 (ERK1/2 inhibitor) can suppress the in vitro activation of Akt and ERK1/2 in molm-14 cells, i.e., in a cellular model of FLT3-ITD-mutated AML, induce the apoptosis of AML cells by promoting the generation of ROS [48].